Russell Investments Group Ltd. Cuts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Russell Investments Group Ltd. lessened its position in AstraZeneca PLC (NASDAQ:AZNGet Rating) by 25.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 796,003 shares of the company’s stock after selling 276,674 shares during the quarter. Russell Investments Group Ltd.’s holdings in AstraZeneca were worth $43,649,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of AZN. Better Money Decisions LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at $25,000. Parkside Financial Bank & Trust increased its holdings in AstraZeneca by 4,875.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after purchasing an additional 390 shares during the period. HHM Wealth Advisors LLC purchased a new stake in AstraZeneca during the 2nd quarter worth about $28,000. Hazlett Burt & Watson Inc. increased its holdings in AstraZeneca by 129.5% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 514 shares of the company’s stock worth $28,000 after purchasing an additional 290 shares during the period. Finally, Fairfield Bush & CO. purchased a new stake in AstraZeneca during the 1st quarter worth about $28,000. Hedge funds and other institutional investors own 16.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AZN. Guggenheim cut their price target on AstraZeneca from £120 ($148.57) to £118 ($146.09) in a report on Tuesday, October 11th. Berenberg Bank upped their price target on AstraZeneca from GBX 118 ($1.46) to GBX 126 ($1.56) in a report on Wednesday, January 18th. JPMorgan Chase & Co. upped their price objective on AstraZeneca from £125 ($154.76) to £135 ($167.14) in a research report on Tuesday, January 3rd. StockNews.com assumed coverage on AstraZeneca in a research report on Wednesday, October 12th. They set a “buy” rating for the company. Finally, TheStreet raised AstraZeneca from a “c” rating to an “a” rating in a research report on Monday, December 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9,510.67.

AstraZeneca Stock Down 2.0 %

Shares of NASDAQ AZN opened at $66.28 on Wednesday. The firm has a market cap of $205.39 billion, a PE ratio of 98.93, a PEG ratio of 1.24 and a beta of 0.53. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 52-week low of $52.65 and a 52-week high of $72.12. The firm has a 50-day moving average price of $68.30.

AstraZeneca (NASDAQ:AZNGet Rating) last announced its earnings results on Thursday, November 10th. The company reported $0.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.07. The firm had revenue of $10.98 billion during the quarter, compared to analysts’ expectations of $10.98 billion. AstraZeneca had a return on equity of 29.40% and a net margin of 4.52%. Sell-side analysts anticipate that AstraZeneca PLC will post 3.33 earnings per share for the current year.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.